The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) is a huge mover today! The stock decreased 4.45% or $1.516 during the last trading session, reaching $32.584. About 239,337 shares traded. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 20.40% since March 14, 2017 and is uptrending. It has outperformed by 3.70% the S&P500.The move comes after 8 months negative chart setup for the $1.20B company. It was reported on Mar, 14 by Barchart.com. We have $29.65 PT which if reached, will make NASDAQ:RVNC worth $107.55M less.
BOE VARITRONIX LTD. ORDINARY SHARES (OTCMKTS:VARXF) had a decrease of 35.84% in short interest. VARXF’s SI was 201,000 shares in March as released by FINRA. Its down 35.84% from 313,300 shares previously. The SI to BOE VARITRONIX LTD. ORDINARY SHARES’s float is 0.07%. It closed at $0.63 lastly. It is down 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.
Since September 20, 2017, it had 0 buys, and 5 insider sales for $2.17 million activity. Browne L Daniel sold $200,405 worth of stock or 7,662 shares. Shares for $297,760 were sold by SILVERNAIL LAUREN P.
Among 12 analysts covering Revance Therapeutics (NASDAQ:RVNC), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Revance Therapeutics had 27 analyst reports since August 22, 2015 according to SRatingsIntel. The rating was downgraded by Zacks to “Hold” on Saturday, August 22. The firm earned “Buy” rating on Tuesday, October 24 by Cantor Fitzgerald. Piper Jaffray maintained it with “Buy” rating and $48.0 target in Thursday, March 1 report. As per Tuesday, December 5, the company rating was initiated by Guggenheim. The firm has “Buy” rating given on Wednesday, December 6 by Mizuho. As per Thursday, November 16, the company rating was maintained by Cantor Fitzgerald. SunTrust maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) rating on Friday, December 8. SunTrust has “Buy” rating and $53.0 target. On Thursday, November 2 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Mizuho initiated Revance Therapeutics, Inc. (NASDAQ:RVNC) rating on Thursday, November 16. Mizuho has “Buy” rating and $37.0 target. The firm has “Buy” rating given on Monday, November 27 by Barclays Capital.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company has market cap of $1.20 billion. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It currently has negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.
Investors sentiment increased to 2.8 in 2017 Q3. Its up 1.80, from 1 in 2017Q2. It is positive, as 12 investors sold Revance Therapeutics, Inc. shares while 25 reduced holdings. 8 funds opened positions while 29 raised stakes. 27.21 million shares or 0.30% less from 27.29 million shares in 2017Q2 were reported. 249,200 were accumulated by Fmr Ltd. Nationwide Fund Advsr holds 0% or 29,130 shares in its portfolio. Utd Services Automobile Association stated it has 58,966 shares. Vanguard Grp has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC). Moreover, Legal & General Group Public Ltd has 0% invested in Revance Therapeutics, Inc. (NASDAQ:RVNC). Ny State Common Retirement Fund holds 23,300 shares or 0% of its portfolio. Susquehanna Intll Group Limited Liability Partnership holds 73,862 shares or 0% of its portfolio. Essex Woodlands Health Ventures holds 22.44% or 4.59M shares. California State Teachers Retirement has invested 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC). Renaissance Tech Ltd Liability holds 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 79,792 shares. Morgan Stanley holds 0% or 126,772 shares. Tiaa Cref Inv Limited Liability Corp invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Wells Fargo And Mn stated it has 18,957 shares or 0% of all its holdings. 203,020 are owned by Geode Capital Mgmt. Voya Mgmt Limited Liability Co invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC).
Analysts await Revance Therapeutics, Inc. (NASDAQ:RVNC) to report earnings on May, 8. They expect $-0.69 earnings per share, up 26.60% or $0.25 from last year’s $-0.94 per share. After $-1.14 actual earnings per share reported by Revance Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -39.47% EPS growth.